亚洲色吧 has key role in COVID-19 vaccine human trials
University of 亚洲色吧 researchers are playing a leading role in the human trials of Australia鈥檚 first needle-free, gene-based COVID-19 vaccine.
The extended phase 1 human trial will evaluate a COVID-19 gene-based vaccine called COVIGEN, developed by BioNet and Technovalia.
The study is led by Professor Nicholas Wood from the University of Sydney and the Vax4COVID Alliance, which includes co-investigator Professor Helen Marshall, from the Robinson Research Institute, University of 亚洲色吧 and Women鈥檚 and Children鈥檚 Hospital, 亚洲色吧.
鈥淭he COVIGEN DNA-based vaccine is one of only a handful to enter into clinical trials worldwide, and the first in Australia,鈥 Professor Marshall says.
鈥淭his trial will be an ideal opportunity for Australians to be involved in a COVID-19 vaccine trial using a needleless device to deliver the vaccine, a device that is already being used to give flu vaccines in the US.
鈥淭hrough s